Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (5): 807-809    DOI: 10.31083/j.ceog.2020.05.5238
Case Report Previous articles |
A novel effective treatment for menière’s disease – dextroamphetamine sulfate
J.H. Check1, 2, *(), D. Check2, R. Cohen1, 2
1Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, 08103 NJ, United States
2Cooper institute for reproductive hormonal disorders, p.c. mt. laurel, 08054 nj, United States
Download:  PDF(141KB)  ( 112 ) Full text   ( 11 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: To determine if treatment with dextroamphetamine sulfate could ameliorate the symptoms of long-standing Menière’s disease in a menopausal woman with a past history of dysmenorrhea. Methods: Dextroamphetamine sulfate was started at 9.4 mg extended release tablets and eventually increased to 18.8 mg (Adzenys®). Results: The symptoms of constant ear fullness and severe tinnitus abated and have not returned for 2 years. In addition, the edema of the fingers and ankles have abated along with an 11 pound weight loss. Conclusions: Menière's disease can be added to the long list of chronic treatment resistant conditions lumped together under the name of the increased cellular permeability syndrome. This syndrome may or may not be associated with pelvic pain. The common denominator is that these seemingly unrelated conditions affecting many organ systems all respond markedly well to amphetamine therapy. The hypothesis of the efficacy of dextroamphetamine sulfate is that it releases dopamine from sympathetic nerve fibers, which, in turn, diminishes cellular permeability.
Key words:  Menière’s disease      Increased cellular permeability syndrome      Dextroamphetamine sulfate      Dopamine      Dysmenorrhea     
Submitted:  18 April 2019      Accepted:  10 June 2019      Published:  15 October 2020     
*Corresponding Author(s):  JEROME H. CHECK     E-mail:  laurie@ccivf.com

Cite this article: 

J.H. Check, D. Check, R. Cohen. A novel effective treatment for menière’s disease – dextroamphetamine sulfate. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 807-809.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2020.05.5238     OR     https://ceog.imrpress.com/EN/Y2020/V47/I5/807

[1] J.H. Check, D. Check. The increased cellular permeability syndrome manifesting as severe idiopathic type urinary incontinence[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 812-814.
[2] H. Kwon, J.E. Shin, H. Kim. A novel treatment of severe dysmenorrhea due to adenomyosis: a case series of 3 infertile patients treated with dopamine agonist and in vitro fertilization-embryo transfer resulting in successful pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 637-640.
[3] J.H. Check, R. Cohen. Sympathomimetic amine therapy abrogates severe long-term unexpalined abdominal pain and diarrhea (microscopic colitis) - possible infertility implications[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 489-491.
[4] J.H. Check, D.L. Check, M.P. Dougherty. Marked improvement of the aromatase induced arthralgia syndrome following treatment with dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 291-292.
[5] J.H. Check, M.P. Dougherty, D.L. Check. Long standing post-herpetic neuralgia resistant to standard anti-neuropathy medication showing quick dramatic improvement following treatment with sympathomimetic amines[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 335-336.
[6] J.H. Check, M. Citerone, T. Citerone. The increased cellular permeability syndrome as a cause of traumatic stuttering[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 773-774.
[7] Ju-Qi Ma, Chun-Fen Guo, Ayshamgul Hasim. Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 387-390.
[8] J.H. Check. Changing the name of a syndrome: sympathetic neural hyperalgesia edema syndrome becomes – the increased cellular permeability syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 819-823.
[9] J.H. Check, R. Cohen. Amelioration of severe generalized idiopathic pruritus in an estrogen deficient woman taking an aromatase inhibitor for breast cancer following treatment with amphetamine salts[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 934-935.
[10] L. Roncati, T. Pusiol. Arteriovenous malformations (AVM) of the corpus uteri[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(5): 764-766.
[11] M. Temur, U. Gök Balci, Y. A. Güçlü, B. Korkmaz, P.Ö. Özbay, N. Soysal, Ö. Yilmaz, T.T. Yilmazer, T. Çift, K. Öngel. Does increase in body mass index effect primary dysmenorrhea?[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(5): 777-781.
[12] J. H. Check, R. Cohen. Marked improvement of severe gastroparesis following high dosage, but very well tolerated, dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(4): 611-612.
[13] M. Zu, W. Meng, Q.Z. Guo, Z.Q. Liu. Deep infiltrating endometriosis in young women[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 268-271.
[14] J.H. Check, A. Jaffe. Dextroamphetamine sulfate provided quick relief of severe post-partum depression that was recalcitrant to standard antidepressants and psychotherapy[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 272-274.
[1] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[2] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[3] Wang Xiaoyin, Zhao Qingping, Yan Mei, Yi HongYing. Diagnosis and treatment of cervical ectopic decidua during pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 428 -432 .
[4] Sung Taek Park, Hye-yon Cho, Sung-ho Park. Clinical comparison of minimal invasive hysterectomy techniques: laparoscopic hysterectomy vs. vaginal hysterectomy[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 503 -507 .
[5] E.S. Yılmaz, T. Sapmaz, H. Kazgan, S. Menziletoglu Yıldız, D. Kocamaz, N. Akpolat, E. Sapmaz. Examination of the effect of melatonin use before hysterosalpingography on ovarian follicle reserve in rats[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 570 -574 .
[6] Tao Cui, Yiqi Zhao, Wenli Zhang, Qiang Yao. Uterine prolapse with complete placenta praevia and umbilical hernia in pregnancy: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 602 -604 .
[7] B. Dullaert, S. Schroven, Y. Jacquemyn. The effect of maternal vitamin D status on pregnancy outcome and child health in the first year of life[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 677 -681 .
[8] K. Lachowski, M. Lachowska, D. Paluszyńska, B. Królak-Olejnik. Two-headed twin in a triplet pregnancy after in vitro fertilization – A case report and review of the literature [J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 782 -786 .
[9] A.H. Kaya, E. Tekgunduz, S. Akpınar, G. Bozdağ, T.N. Yiğenoğlu, A. Merdin, S. Namdaroglu, O. Kayıkcı, F. Altuntaş. Assessment of ovarian reserve with anti-Mullerian hormone in women following allogeneic hematopoietic cell transplantation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 127 -130 .
[10] L.-S. Wang, X.-L. Zhao, X.-A. Cai, G.-F. Fu. Age specific reference intervals of serum anti-MÁllerian hormone concentration of 1,253 women with healthy females in infertility center[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 526 -530 .